Physician

Mark D Kochenderfer, MD

According to 2025 Medicare claims, Mark Kochenderfer, MD (NPI: 1396720454) practices hematology/oncology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (NPI: 1487621496; TIN: 541922084) and primary practice location at 24014-2419.

Kochenderfer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 853 traditional Medicare patients, billed 162,044 HCPCS/CPT codes, and received $3,427,351 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,488 prescription claims across 306 beneficiaries totaling $5,592,053 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 130 claims. Open Payments data shows 250 records totaling $1,052,227. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,123,676 to $3,427,351. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,415,195 to $5,592,053. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,357 to $184.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	886	202,184	$2,123,676
2016	956	167,324	$2,517,172
2017	1,027	186,842	$2,966,506
2018	1,066	195,258	$2,832,566
2019	1,033	199,810	$3,090,819
2020	1,007	237,782	$4,203,915
2021	991	203,999	$3,696,389
2022	989	195,730	$3,588,840
2023	903	192,927	$3,664,608
2024	853	162,044	$3,427,351

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	286	1,531	$1,415,195
2016	292	1,524	$1,236,510
2017	319	1,579	$1,398,488
2018	318	1,558	$1,622,772
2019	302	1,474	$2,042,521
2020	314	1,535	$2,890,852
2021	290	1,370	$2,657,523
2022	278	1,242	$3,731,666
2023	284	1,238	$4,195,402
2024	306	1,488	$5,592,053

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	37	$3,574
2016	N/R	81	$25,299
2017	N/R	63	$19,381
2018	53	152	$21,470
2019	61	154	$17,016
2020	100	269	$23,664
2021	49	202	$14,675
2022	67	249	$10,163
2023	67	235	$40,095
2024	31	130	$4,035

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	271	642	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	303	406	$57
80053	Blood test, comprehensive group of blood chemicals	371	1,186	$10
36415	Insertion of needle into vein for collection of blood sample	393	897	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	389	1,431	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	93	2,790	$1,314,714
Ibrance	Palbociclib	40	1,120	$641,272
Tasigna	Nilotinib Hcl	27	756	$539,278
Xtandi	Enzalutamide	28	840	$375,676
Orserdu	Elacestrant Hcl	16	480	$360,628

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	12	33	$1,414
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	19	52	$960
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	20	$751
J8700	Temozolomide, oral, 5 mg	N	N/R	12	$748
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$107	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	244	$1,052,121	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark D. Kochenderfer, MD?

Tedicare shows public-source Medicare data for Mark D. Kochenderfer, MD (NPI 1396720454), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark D. Kochenderfer, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark D. Kochenderfer, MD?

Mark D. Kochenderfer, MD is linked to ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (billing NPI 1487621496) in the available physician profile data.

Does Mark D. Kochenderfer, MD have Open Payments data?

Mark D. Kochenderfer, MD has 250 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.